BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/9/2026 8:15:16 AM | Browse: 2 | Download: 5
 |
Received |
|
2026-03-18 06:34 |
|
Peer-Review Started |
|
2026-03-18 06:34 |
|
First Decision by Editorial Office Director |
|
2026-06-04 07:46 |
|
Return for Revision |
|
2026-06-04 11:51 |
|
Revised |
|
2026-06-16 13:55 |
|
Publication Fee Transferred |
|
2026-06-23 13:54 |
|
Second Decision by Editor |
|
2026-07-09 02:35 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-07-09 08:22 |
|
Articles in Press |
|
2026-07-09 08:22 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-09-08 10:07 |
|
Publish the Manuscript Online |
|
2026-10-09 08:15 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Clinical application of a programmed death ligand-1 inhibitor combined with low-dose pulsed radiotherapy in recurrent metastatic hepatocellular carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xin-An Wan, Ming-Xing Fang, Le Yuan, Hang Zhang, Dan Wang and Zhao-Di Liu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Clinical Medical Research Transformation Project of Anhui Province of China |
No. 202204295107020064 |
|
| Corresponding Author |
Xin-An Wan, Chief Physician, MD, PhD, Department of Oncology, The Second People’s Hospital, Wuhu, No. 6 Duchun Road, Wuhu 241000, Anhui Province, China. 2263853630@qq.com |
| Key Words |
Programmed death ligand-1 inhibitor; Pulsed radiotherapy; Hepatocellular carcinoma; Clinical application; T lymphocyte subsets |
| Core Tip |
The combination of a programmed death ligand-1 inhibitor (atezolizumab) and low-dose pulsed radiation therapy has shown good efficacy and safety in some patients with recurrent metastatic hepatocellular carcinoma. |
| Publish Date |
2026-10-09 08:15 |
| Citation |
Wan XA, Fang MX, Yuan L, Zhang H, Wang D, Liu ZD. Clinical application of a programmed death ligand-1 inhibitor combined with low-dose pulsed radiotherapy in recurrent metastatic hepatocellular carcinoma. World J Gastrointest Oncol 2026; 18(10): 121184
|
| URL |
https://www.wjgnet.com/1948-5204/full/v18/i10/121184.htm |
| DOI |
https://doi.org/10.4251/wjgo.121184 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
